MedTrace Logo

High Dose Ascorbic Acid for Plasma Cell Disorders

NCT03602235 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-10-21

No results posted yet for this study

Summary

This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.

Conditions

Interventions

OTHER

Ascorbate

Ascorbate is in the vitamin drug class

DRUG

Melphalan

Melphalan is an alkylating agent coupled to an amino acid

Sponsors & Collaborators

  • University of Iowa

    collaborator OTHER

  • Christopher Strouse

    lead OTHER

Principal Investigators

  • Christopher Strouse, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2024-07-01
Completion
2025-09-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03602235 on ClinicalTrials.gov